by Stacey Johnson | Nov 12, 2021
In 2016 I shared a list of podcasts that I thought Signals’ readers might enjoy. I think it’s definitely time to update that list, and I’m excited to tell you about a new podcast that’s about to launch: Commercializing Living Therapies with CCRM. Commercializing...
by Tara Fernandez | Jul 7, 2021
In early 2021, a young boy in Barcelona was the first to receive Pfizer’s investigational gene therapy for Duchenne muscular dystrophy (DMD). This was part of a global Phase 3 human trial to test Pfizer’s lead candidate, PF-06939926, in a cohort of 99 patients with...
by Stacey Johnson | Jun 25, 2021
Back in November 2020, California voters approved Proposition 14. That means US$5.5B is being directed to the California Institute for Regenerative Medicine (CIRM) to support promising cell and gene therapy research so the organization can continue the important work...
by Stacey Johnson | Feb 12, 2021
Canada is a country that prides itself on “punching above its weight.” We use this metaphor all the time to describe how we succeed in given situations despite our limitations. Although it’s a cliché, it remains a point of pride for Canadians. For example, in the...
by CCRM Australia | Dec 10, 2020
Dr. Chih Wei Teng is Chief Operating Officer for CCRM Australia. Regulatory reforms, significant investments into infrastructure and focused grand challenge programs are very much like an economic and science arms race to develop the next blockbuster or vaccine, such...
by Stacey Johnson | Oct 16, 2020
The news that Health Canada has approved gene therapy Luxturna to treat blindness couldn’t come at a better time, as October is Blindness Awareness Month. You don’t have to look far to find other high impact research on blindness happening right here in Toronto,...
Comments